Update in General Internal Medicine
Authors: John V.L. Sheffield
Journal: Annals of Internal Medicine (1997)

Updates1 July 1997Update in General Internal MedicineJohn V.L. Sheffield, MD and Eric B. Larson, MD, MPHJohn V.L. Sheffield, MD1997-98 Series John Roberts, MD, Editor.From Harborview Medical Center and the University of Washington Medical Center, Seattle, Washington. and Eric B. Larson, MD, MPH1997-98 Series John Roberts, MD, Editor.From Harborview Medical Center and the University of Washington Medical Center, Seattle, Washington.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-127-1-199707010-00008 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Advances in general internal medicine have come quickly and from a wide diversity of sources in the past year or two. Clearly, it is impossible for one or two general internists to reliably identify the most significant clinical advances. We therefore asked 13 general internists at the University of Washington to answer the question, “What were the five most important papers or most important advances you read about in the past year?” From among their responses, we selected those papers that focused on common and clinically relevant problems and circulated the relevant papers to the editors of ACP Journal Club ...References1. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med. 1996; 335:1081-90. Google Scholar2. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee. Lancet. 1996; 348:283-91. Google Scholar3. Saravolatz LD, Winslow DL, Collins G, Hodges JS, Pettinelli C, Stein DS, et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 1996; 335:1099-106. Google Scholar4. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med. 1996; 334:1011-7. Google Scholar5. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996; 272:1167-70. Google Scholar6. Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA. Coombs R, Poscher ME, et al. HIV viral load markers in clinical practice. Nat Med. 1996; 2:626-9. Google Scholar7. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA. 1996; 276:146-54. Google Scholar8. Every NR, Parsons LS, Hlatky M, Martin JS, Weaver WD. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. Myocardial Infarction Triage and Intervention Group. N Engl J Med. 1996; 335:1253-60. Google Scholar9. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization (BARI) Investigators. N Engl J Med. 1996; 335:217-25. Google Scholar10. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med. 1996; 335:1001-9. Google Scholar11. Randomised trial of cholesterol lowering in 4444 patients with coronary artery disease: the Scandinavian Simvastatin Survival Study (4S). Scandinavian Simvistatin Survival Study Group. Lancet. 1994; 344:1383-9. Google Scholar12. Dargie HJ, McMurray JJ, McDonagh TA. Heart failure-implications of the true size of the problem. J Intern Med. 1996; 239:309-15. Google Scholar13. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996; 334:1349-55. Google Scholar14. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med. 1997; 336:525-33. Google Scholar15. Soumerai SB, McLaughlin TJ, Spiegelman D, Hertzmark E, Thibault G, Goldman L. Adverse outcomes of underuse of β-blockers in elderly survivors of acute myocardial infarction. JAMA. 1997; 277:115-21. Google Scholar16. Espeland MA, Kumanyika S, Kostis JB, Algire J, Applegate WB, Ettinger W, et al. Antihypertensive medication use among recruits for the Trial of Nonpharmacologic Interventions in the Elderly (TONE). J Am Geriatr Soc. 1996; 44:1183-9. Google Scholar17. de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996; 335:1016-21. Google Scholar18. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing verterbral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348:1535-41. Google Scholar19. Stergachis A, Scholes D, Heidrich FE, Sherer DM, Holmes KK, Stamm WE. Selective screening for Chlamydia trachomatis infection in a primary care population of women. Am J Epidemiol. 1993; 138:143-53. Google Scholar20. Long-term pharmacotherapy in the management of obesity. National Task Force on the Prevention and Treatment of Obesity. JAMA. 1996; 276:1907-15. Google Scholar21. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of β-carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996; 334:1150-5. Google Scholar Author, Article, and Disclosure InformationAffiliations: 1997-98 Series John Roberts, MD, Editor.From Harborview Medical Center and the University of Washington Medical Center, Seattle, Washington.Corresponding Author: Eric B. Larson, MD, University of Washington Medical Center, Room AA 316, Box 356330, Seattle, WA 98195-4021.Current Author Addresses: Dr. Sheffield: Harborview Medical Center, Box 359782, 325 Ninth Avenue, Seattle, WA 98104. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAdequacy of anticoagulation in patients with atrial fibrillation: Effect of various parameters 1 July 1997Volume 127, Issue 1Page: 43-51KeywordsAcute myocardial infarctionAtrial fibrillationClinical trialsDrugsDysthmiaHypertensionNumber needed to treatOsteoporosisPulmonary hypertensionStroke Issue Published: 1 July 1997 Copyright & PermissionsCopyright © 1997 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...